Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model
- Andrew K. Powell, Steven D. Shnyder, +4 authors G. Smith
- Medicine
- 10 December 2009
CYT997 is an orally bioavailable small molecule vascular‐disrupting agent (VDA) that is currently being investigated in Phase II clinical studies. In vitro efficacy studies have demonstrated that… Expand
The Evaluation of Selected Ghanaian Medicinal Plants for Cytotoxic Activities
- M. Bayor, J. S. K. Ayim, R. Phillips, Steven D. Shnyder, C. Wright
- Medicine
- 10 April 2008
Cancer is still responsible for many deaths worldwide. Therefore, the need for an effective management, treatment and cure of cancer is undoubtedly crucial. In Ghana, several plants or herbal… Expand
Abstract 1774: Polysialyltransferase ST8SiaII: a new target for the treatment of metastatic tumors
- V. Viprey, Bradley R. Springett, +7 authors R. Falconer
- Biology
- 1 October 2014
Polysialic acid (polySia) is a carbohydrate polymer expressed on the surface of NCAM (neuronal cell adhesion molecule) in many cancer cells where it modulates cell-cell and cell-matrix adhesion,… Expand
A Cytotoxic Diterpenoid from Croton Membranaceus, the Major Constituent of Anticancer Herbal Formulations Used in Ghana
- M. Bayor, J. S. K. Ayim, +4 authors C. Wright
- Chemistry
- 1 November 2008
Croton membranaceus is used by herbalists and traditional healers in Ghana for the management of various cancers, especially prostate cancers. A methanolic extract of the roots showed cytotoxic… Expand
Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines
- M. Ahmed, Haneen A. Basheer, +6 authors K. Afarinkia
- Biology, Medicine
- Scientific Reports
- 21 April 2017
We describe a novel protocol to quantitatively and simultaneously compare the chemotactic responses of cells towards different chemokines. In this protocol, droplets of agarose gel containing… Expand
Probing cytochrome P450-mediated activation with a truncated azinomycin analogue
- V. Vinader, M. Sadiq, +9 authors K. Pors
- Chemistry
- 5 January 2015
A deactivated alkene precursor (IC50 = 81 μM) to the azinomycin epoxide natural product can be bioactivated by several cytochromes P450 (CYP) to generate antiproliferative metabolites with increased… Expand
Abstract 736: Pyridinobenzodiazepines (PDDs): A new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity
- N. Veillard, Paolo Andriollo, +13 authors D. Thurston
- Chemistry
- 1 July 2018
Although four ADCs have been approved and over sixty others are in development, the majority contain payloads belonging to two classes; tubulin inhibitors and DNA cross-linkers. Challenges in the… Expand
Evaluation of Alangium lamarckii Bark for Antiplasmodial and Cytotoxic Constituents and Isolation of a Novel Tubulosine Analogue
- V. S. S. N. Kantamreddi, G. Marston, Steven D. Shnyder, C. Wright
- Chemistry
- 1 October 2018
Alangium lamarkii is traditionally used in India for the treatment of malaria. Partial activity guided-fractionation of the basic chloroform fraction of the methanolic extract of the bark led to the… Expand
Abstract 5431: Polysialyltransferase ST8SiaII: A novel target for the treatment of neuroblastoma
- Sara M. Elkashef, V. Viprey, +6 authors R. Falconer
- Chemistry
- 1 August 2015
Polysialic acid (polySia) is a carbohydrate polymer expressed on the surface of NCAM (neuronal cell adhesion molecule) in many cancer cells where it modulates cell-cell and cell-matrix adhesion,… Expand
Abstract #LB-211: CYT997: Preclinical studies on the antivascular effects and mode of action of a phase II vascular disrupting agent.
- D. Segal, P. Gangatirkar, +7 authors E. Fantino
- Medicine
- 1 May 2009
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO
CYT997 is an orally available synthetic small molecule that is currently in phase II clinical studies within different oncology settings. CYT997 has… Expand